Lack of Fibronectin-EDA Promotes Survival and Prevents Adverse Remodeling and Heart Function Deterioration After Myocardial Infarction
暂无分享,去创建一个
Gerard Pasterkamp | Imo E Hoefer | Fatih Arslan | P. Doevendans | P. Quax | G. Pasterkamp | J. Peters | M. Smeets | D. D. de Kleijn | L. Bongartz | I. Hoefer | F. Arslan | J. Karper | Pieter A Doevendans | Mirjam B Smeets | Paul W Riem Vis | Jacco C Karper | Paul H Quax | Lennart G Bongartz | John H Peters | Dominique P de Kleijn | P. W. Riem Vis
[1] B. Rollins,et al. CCL2/Monocyte Chemoattractant Protein-1 Regulates Inflammatory Responses Critical to Healing Myocardial Infarcts , 2005, Circulation research.
[2] M. Ginsberg,et al. Integrin‐associated proteins as potential therapeutic targets , 2008, Immunological reviews.
[3] J. Sluijter,et al. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. , 2008, Atherosclerosis.
[4] R Roberts,et al. Deleterious effects of methylprednisolone in patients with myocardial infarction. , 1976, Circulation.
[5] L. Sklar,et al. Intravascular release of intact cellular fibronectin during oxidant-induced injury of the in vitro perfused rabbit lung. , 1986, The Journal of clinical investigation.
[6] H. Ogawa,et al. The extra domain A of fibronectin stimulates murine mast cells via Toll‐like receptor 4 , 2007, Journal of leukocyte biology.
[7] T. Doetschman,et al. Origin of Cardiac Fibroblasts and the Role of Periostin , 2009, Circulation research.
[8] J. Peters,et al. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. , 2004, Blood.
[9] N. Frangogiannis. The immune system and cardiac repair. , 2008, Pharmacological research.
[10] K. Sekiguchi,et al. Alternatively Spliced EDA Segment Regulates Fibronectin-dependent Cell Cycle Progression and Mitogenic Signal Transduction* , 1999, The Journal of Biological Chemistry.
[11] B. Keogh,et al. TLR2 and TLR4 in Ischemia Reperfusion Injury , 2010, Mediators of inflammation.
[12] E. Verrier,et al. Inhibition of Toll-like Receptor 4 With Eritoran Attenuates Myocardial Ischemia-Reperfusion Injury , 2006, Circulation.
[13] M. Cunningham,et al. Cutting Edge: Cardiac Myosin Activates Innate Immune Responses through TLRs1 , 2009, The Journal of Immunology.
[14] A. Geinoz,et al. The Fibronectin Domain ED-A Is Crucial for Myofibroblastic Phenotype Induction by Transforming Growth Factor-β1 , 1998, Journal of Cell Biology.
[15] K. Miyake. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. , 2007, Seminars in immunology.
[16] P. Doevendans,et al. Myocardial Ischemia / Reperfusion Injury Is Mediated by Leukocytic Toll-Like Receptor-2 and Reduced by Systemic Administration of a Novel Anti – Toll-Like Receptor-2 Antibody , 2009 .
[17] P. Doevendans,et al. Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. , 2008, Current pharmaceutical design.
[18] M. Ginsberg,et al. Release of soluble fibronectin containing an extra type III domain (ED1) during acute pulmonary injury mediated by oxidants or leukocytes in vivo. , 1988, The American review of respiratory disease.
[19] Minoru Hongo,et al. Cardiac Overexpression of Monocyte Chemoattractant Protein-1 in Transgenic Mice Prevents Cardiac Dysfunction and Remodeling After Myocardial Infarction , 2006, Circulation research.
[20] R. Alon,et al. Integrin modulation and signaling in leukocyte adhesion and migration , 2007, Immunological reviews.
[21] B. Yawn,et al. Trends in heart failure incidence and survival in a community-based population. , 2004, JAMA.
[22] G. Wang,et al. Divergent Tumor Necrosis Factor Receptor-Related Remodeling Responses in Heart Failure: Role of Nuclear Factor-&kgr;B and Inflammatory Activation , 2009, Circulation.
[23] D. Sheppard,et al. The EIIIA Segment of Fibronectin Is a Ligand for Integrins α9β1 and α4β1Providing a Novel Mechanism for Regulating Cell Adhesion by Alternative Splicing* , 2002, The Journal of Biological Chemistry.
[24] M. Pfeffer,et al. Which Inhibitor of the Renin–Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? , 2004, Circulation.
[25] R. Hynes,et al. Biosynthesis and processing of fibronectin in NIL.8 hamster cells. , 1979, The Journal of biological chemistry.
[26] M. Goumans,et al. Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction , 2008, Circulation research.
[27] H. Drexler,et al. The renin-angiotensin system and experimental heart failure. , 1999, Cardiovascular research.
[28] P. Matzinger. The Danger Model: A Renewed Sense of Self , 2002, Science.
[29] A. Takeshita,et al. Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction , 2002, Circulation.
[30] G. Pasterkamp,et al. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. , 2005, Cardiovascular research.
[31] Jerome F. Strauss,et al. The Extra Domain A of Fibronectin Activates Toll-like Receptor 4* , 2001, The Journal of Biological Chemistry.
[32] I. Kubota,et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. , 2008, Cardiovascular research.
[33] Francis G Spinale,et al. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.